Abstract
Bacillus licheniformis α-amylase (BLA) is routinely used as a model thermostable amylase in biochemical studies. Its starch hydrolysis activity has recently been studied in Tris buffer. Here, we address the question that whether the application of Tris buffer may influence the results of BLA activity analyses. Based on the inhibition studies and docking simulations, we suggest that Tris molecule is a competitive inhibitor of starch-hydrolyzing activity of BLA, and it has a high tendency to bind the enzyme active site. Hence, it is critically important to consider such effect when interpreting the results of activity studies of this enzyme in Tris buffer.
Keywords: BLA, Tris inhibition, buffer inhibition, activity, docking, French bean, glucuronic acid, lectin, mitogenic activity, HepG2, breast cancer, glycoproteins, N-acetylgalactosamine-binding, polysaccharides, inflammation,, thrombosis, metastasis, Phaseolus vulgaris, AKTA Purifier, PBS, SDS-PAGE, HPLC, MCF7, CNE1, CNE2, MTT, Affi-gel blue gel, FPLC, hemagglutinating, N-acetylglucosamine, Aprotinin, Ovalbumin, Temperature, CNE, PHAs, ATP, Con A, chromatography, gel filtration, anti-HIV reverse transcriptase
Protein & Peptide Letters
Title: Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity
Volume: 15 Issue: 2
Author(s): Zahra Ghalanbor, Nasser Ghaemi, Sayed-Amir Marashi, Massoud Amanlou, Mehran Habibi-Rezaei, Khosro Khajeh, Bijan Ranjbar, Yau Sang Chan, Jack Ho Wong and Tzi Bun Ng
Affiliation:
Keywords: BLA, Tris inhibition, buffer inhibition, activity, docking, French bean, glucuronic acid, lectin, mitogenic activity, HepG2, breast cancer, glycoproteins, N-acetylgalactosamine-binding, polysaccharides, inflammation,, thrombosis, metastasis, Phaseolus vulgaris, AKTA Purifier, PBS, SDS-PAGE, HPLC, MCF7, CNE1, CNE2, MTT, Affi-gel blue gel, FPLC, hemagglutinating, N-acetylglucosamine, Aprotinin, Ovalbumin, Temperature, CNE, PHAs, ATP, Con A, chromatography, gel filtration, anti-HIV reverse transcriptase
Abstract: Bacillus licheniformis α-amylase (BLA) is routinely used as a model thermostable amylase in biochemical studies. Its starch hydrolysis activity has recently been studied in Tris buffer. Here, we address the question that whether the application of Tris buffer may influence the results of BLA activity analyses. Based on the inhibition studies and docking simulations, we suggest that Tris molecule is a competitive inhibitor of starch-hydrolyzing activity of BLA, and it has a high tendency to bind the enzyme active site. Hence, it is critically important to consider such effect when interpreting the results of activity studies of this enzyme in Tris buffer.
Export Options
About this article
Cite this article as:
Ghalanbor Zahra, Ghaemi Nasser, Marashi Sayed-Amir, Amanlou Massoud, Habibi-Rezaei Mehran, Khajeh Khosro, Ranjbar Bijan, Sang Chan Yau, Ho Wong Jack and Bun Ng Tzi, Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity, Protein & Peptide Letters 2008; 15 (2) . https://dx.doi.org/10.2174/092986608783489616
DOI https://dx.doi.org/10.2174/092986608783489616 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Application of Connected QSRR and QSAR Strategies to Predict the Physicochemical Interaction of Acridinone Derivatives with DNA
Combinatorial Chemistry & High Throughput Screening Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science The Role of Methionine Oxidation/Reduction in the Regulation of Immune Response
Current Signal Transduction Therapy Subject Index To Volume 8
Current Pharmaceutical Design Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies
Recent Patents on DNA & Gene Sequences The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design New Insights into Neoangiogenesis and Breast Cancer Development and Progression
Current Angiogenesis (Discontinued) Anticancer Activity and In Silico ADMET Properties of 2,4,5-Trisubstitutedthiazole Derivatives
Current Drug Metabolism Editorial: (Thematic Issue Cancer Immunotherapy: Does an Increasing Arsenal of Tools Point to More Fruitful Avenues for Research?)
Anti-Cancer Agents in Medicinal Chemistry Microwave Assisted Synthetic Approach of New Pyridine based Benzothiazepines: Their Antibacterial and Antifungal Activities
Current Microwave Chemistry In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Recent Progress in Biological Activities and Synthetic Methodologies of Pyrroloquinoxalines
Mini-Reviews in Medicinal Chemistry Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies